Testing the safety of tolvaptan in children with ARPKD
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is for children from 28 days old up to 18 years who have a rare kidney disease called ARPKD. It will test if the drug tolvaptan is safe for them. The study helps find new treatment options for kids with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 28 days and 18 years old
- You must have a diagnosis of autosomal recessive polycystic kidney disease (ARPKD)
- You cannot have had a kidney transplant or be on dialysis
- You need to be able to have fluid intake and output monitored
- Your blood sodium levels must be in a safe range
- You must avoid certain medications that could interfere
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the cholesterol-lowering drug bempedoic acid can slow kidney function loss in people with autosomal dominant polycystic kidney disease (ADPKD). It may offer a new option to protect your kidneys.
This study enrolls adults with autosomal dominant polycystic kidney disease (ADPKD) to better understand the disease and its related changes in the body. It may help researchers find improved ways to track the condition and support future treatments.
This study looks at medical records, imaging, and genetic testing for people with autosomal recessive polycystic kidney disease (ARPKD). It may help researchers better understand the condition and how it affects the liver and kidneys.
This registry study collects information about adults with autosomal dominant polycystic kidney disease (ADPKD) who are starting or already taking tolvaptan. It may help researchers understand how tolvaptan is used in real life and what outcomes look like over time.
This study helps people with ADPKD and moderate kidney damage decide together with their doctor whether to start a treatment called tolvaptan. It tests a shared decision-making tool to see if it helps patients understand their options better.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
Hear when a new Autosomal Recessive Polycystic Kidney (ARPKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.